San Diego, January 29, 2026
Halozyme Therapeutics, based in San Diego, has significantly increased its revenue forecasts for 2025 and 2026, showcasing strong projected growth driven by strategic acquisitions and investments. The company’s optimism reflects a resilient biotechnology landscape in San Diego, with expected revenue jumps from strategic initiatives that enhance innovative drug delivery systems. As Halozyme thrives, its success is anticipated to positively influence the local economy, fostering job creation and encouraging broader entrepreneurship in the region.
San Diego, California – Halozyme Therapeutics, Inc. (NASDAQ: HALO) recently announced a significant raise in its financial guidance for the years 2025 and 2026, reflecting a pattern of strong performance and strategic growth initiatives. This promising trajectory underscores the resilience of innovation-driven companies in San Diego, highlighting how the city continues to be a hub for entrepreneurial talent and investment. Such growth, if supported by favorable policies and a reduced regulatory burden, can elevate the entire San Diego County economy.
For the full year 2025, Halozyme projects total revenue between $1.385 billion and $1.4 billion, representing an impressive 36% to 38% increase over 2024. This projection also expects royalty revenue to range from $865 million to $870 million, reflecting a robust 51% to 52% growth year-over-year. Adjusted EBITDA for 2025 is forecasted between $885 million and $935 million, marking a 40% to 48% increase. Moreover, non-GAAP diluted earnings per share are set to be between $6.10 and $6.50, indicating a growth of 44% to 54%.
Outlook for 2026
Looking forward to 2026, Halozyme anticipates total revenue between $1.71 billion and $1.81 billion, signaling a 23% to 30% growth over the 2025 estimates. New projections include royalty revenue expected to reach between $1.13 billion and $1.17 billion, which translates to a 30% to 35% increase. Adjusted EBITDA is estimated at $1.125 billion to $1.205 billion. This forecast factors in approximately $60 million in fresh investments in Hypercon™ and Surf Bio, not included in prior guidance. Additionally, non-GAAP diluted earnings per share are projected to lay between $7.75 and $8.25.
Strategic Growth Initiatives
Halozyme’s optimistic growth outlook is underpinned by strategic acquisitions, notably the recent purchase of Elektrofi, which strengthens the company’s abilities in high-concentration drug delivery. This acquisition is pivotal as it aligns with the growing demand for innovative delivery mechanisms in the pharmaceutical sector. Furthermore, the investment in Surf Bio aims to extend Halozyme’s platform well into the 2040s, securing a competitive edge in a rapidly evolving market.
Recent Stock Performance
As of January 29, 2026, Halozyme’s stock is trading at $72.83, reflecting a surge of 3.72% from the previous close. The stock performance is an encouraging signal for potential investors and a testament to the company’s solid fundamentals and bright future as it executes its growth strategy.
Community Implications
Halozyme’s upward trajectory not only showcases individual corporate success but also hints at broader economic implications for San Diego. When companies like Halozyme expand, they foster job creation, stimulate local economies, and encourage other entrepreneurs to innovate, ultimately benefiting the local community. Policymakers in San Diego have a significant role in facilitating such growth through prudent regulations that allow businesses to thrive without unnecessary constraints.
As residents and community members, it is vital to recognize the strength of our local businesses and support initiatives that enable them to reach these ambitious goals. Encouraging a culture of entrepreneurship and maintaining a pro-business environment can drive San Diego to further economic growth and prosperity.
Conclusion
Halozyme Therapeutics’ enhanced financial forecasts for 2025 and 2026 highlight a promising future, not just for the company but for the entire San Diego business landscape. As we witness these developments, the call to action for local residents and entrepreneurs is clear: stay invested in and supportive of our region’s economic potential. Together, we can uplift our businesses and ensure that San Diego remains a beacon of innovation and economic vitality in California.
Frequently Asked Questions (FAQ)
What is Halozyme’s updated revenue guidance for 2025?
Halozyme now anticipates total revenue between $1.385 billion and $1.4 billion for 2025, marking a 36% to 38% increase over 2024. This includes royalty revenue of $865 million to $870 million, representing a 51% to 52% growth from the previous year.
What are Halozyme’s projections for 2026?
For 2026, Halozyme projects total revenue between $1.71 billion and $1.81 billion, indicating a 23% to 30% growth over the 2025 estimate. Royalty revenue is expected to reach $1.13 billion to $1.17 billion, a 30% to 35% increase. Adjusted EBITDA is forecasted at $1.125 billion to $1.205 billion, incorporating approximately $60 million in new investments in Hypercon™ and Surf Bio, which were not included in prior guidance. Non-GAAP diluted earnings per share are projected between $7.75 and $8.25.
What strategic initiatives are contributing to Halozyme’s growth?
Halozyme’s growth is supported by the recent acquisition of Elektrofi, enhancing its capabilities in high-concentration drug delivery, and the strategic investment in Surf Bio, which extends the company’s platform into the 2040s.
What is Halozyme’s current stock performance?
As of January 29, 2026, Halozyme’s stock is trading at $72.83, up 3.72% from the previous close.
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE SAN DIEGO WRITER
The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.